Eficacia y seguridad de tamsulosina para el tratamiento conservador del cólico nefrítico: revisión sistemática con metaanálisis de ensayos clínicos aleatorizados

Camps, Mència Benítez; Herrero, Mercè; Llorente, Noemi de Miguel; Solé, Elisabet; Flores-Mateo, Gemma; Pijoan, Anna M. Pedro; Murillo-Huapaya, Carlos

doi:10.1016/j.medcli.2015.01.029

Cited by 8 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In brief, there was not any significant difference between group A and B in stone free rate, despite the fact that it was higher in group B. Also, in our study, stone clearance rate was lower in comparison with the most earlier studies in groups received tamsulosin (1)(2)(3)(4)(5)12,14,15,(17)(18)(19)(20)(21)(22). Unfortunately, we did not find any similar study to compare our results with it.…”

Section: Discussioncontrasting

confidence: 72%

Efficacy of tamsulosin versus tamsulosin plus lithorex-B as medical expulsive therapy following extracorporeal shock-wave lithotripsy of renal and upper ureteric stones; a randomized clinical trial

Mehrabi¹,

Manzouri²,

Kohzadi³

et al. 2017

J Nephropharmacol

View full text Add to dashboard Cite

Implication for health policy/practice/research/medical education:Further studies are necessary to provide comparison between tamsulosin and lithorex-B in separate groups for deciding about treatment with lithorex-B.Please cite this paper as: Mehrabi S, Manzouri L, Kohzadi A Mehrabi F. Efficacy of tamsulosin versus tamsulosin plus lithorex-B as medical expulsive therapy following extracorporeal shock-wave lithotripsy of renal and upper ureteric stones; a randomized clinical trial.Introduction: Urolithiasis is one of the most common disorders of urinary system. Objectives: To compare the efficacy and safety of tamsulosin versus tamsulosin plus lithorex-B. Patients and Methods:This study was an open-label, randomized, controlled trial conducted in Yasuj University of Medical Sciences, Iran in 2014 to 2015. After taking informed consent, a total of 64 patients aged 18 years and over, presenting with renal or upper ureteral stones up to 20 mm in diameter were enrolled in this study. After extracorporeal shock-wave lithotripsy (SWL), patients were randomly assigned to group A (n = 32) received tamsulosin 0.4 mg and group B (n = 32) received tamsulosin 0.4 mg plus lithorex-B 400 mg orally at bed time daily for 2 weeks. Finally, patients were assessed by KUB and sonography. The stone passage rate, drug adverse effects and pain score were evaluated. All data were analyzed using SPSS 21. Results: There were no significant differences between group A and B regarding stone expulsion rates (40.6% vs 43.7%, P = 0.83), adverse effects (34.4% vs 40.6%, P = 0.79) and mean score of pain (4.31 ± 2.02 vs 5 ± 2.01, P = 0.17) after 2 weeks follow up. Primary stone size was the predicting factor of stone passage (β = -0.42, P = 0.005, Exp (β) = 0.65, CI 95%, Exp (β): 0.48-0.88). Conclusion: Tamsulosin plus lithorex-B is safe and well tolerated with no extra benefit regarding the expulsion rate in 2 weeks follow up. Hence, the necessity of conducting a trial with a longer follow up period providing comparison between tamsulosin and lithorex-B in separate group is felt.

show abstract